ICT&health December 15, 2025
Artur Olesch

“Patients deserve more than to wait 12-15 years for a new drug to come to market. We need AI to change it,” according to Dr Patrick Schorderet, Global Head of AI Execution at Novo Nordisk Research and Development. In an interview for ICT&Health Global, he explains how the pharmaceutical industry is adopting AI and why the company plans to generate more data in 2026 than in the past 50 years.

The pharmaceutical sector is ranked surprisingly low in public trust, even below the oil and gas sector. Can artificial intelligence help regain confidence, and where should the pharmaceutical industry begin?

It’s interesting to see that the public – including the patients – see the pharmaceutical sector as being part of...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety
Introducing the Sunday Times Tech 100: Life sciences part 1

Share Article